Standard Operating Procedure: Pharmacovigilance (PV) Operations

This Standard Operating Procedure (SOP) defines the mandatory processes for the systematic collection, detection, assessment, monitoring, and prevention of adverse effects associated with pharmaceutical products. The primary objective of this SOP is to ensure global regulatory compliance, uphold patient safety, and maintain the integrity of the safety database. This procedure applies to all internal staff, third-party vendors, and stakeholders involved in the intake and processing of safety information.

1. Adverse Event (AE) Intake and Receipt

• Identify Source: Confirm if the incoming report is a valid individual case safety report (ICSR) containing the minimum criteria: an identifiable patient, an identifiable reporter, a suspect drug, and an adverse event.
• Initial Triage: Perform immediate triage to determine the seriousness and expectedness of the event.
• Time-Stamp: Record the exact date and time of receipt (Day 0) to ensure regulatory reporting timelines are met.
• Duplicate Check: Search the safety database for existing cases to prevent duplicate entries for the same patient/event.

2. Case Processing and Data Entry

• Data Capture: Transcribe all relevant medical history, concomitant medications, and event details into the Safety Database.
• Coding: Use standardized medical dictionaries (MedDRA for events, WHODrug for medications) to ensure uniform data classification.
• Causality Assessment: Evaluate the relationship between the drug and the event using clinical judgment and standardized algorithms (e.g., Naranjo Scale).
• Narrative Writing: Construct a clear, concise, and chronological clinical summary of the case, ensuring all redacted personally identifiable information (PII) is handled per GDPR/HIPAA.

3. Medical Review and Quality Control

• Medical Assessment: Assign a Qualified Person for Pharmacovigilance (QPPV) or authorized medical professional to review the clinical accuracy of the case.
• Quality Review: Conduct a secondary check for data integrity, ensuring all fields match the source documentation.
• Final Approval: Sign off on the case closure, confirming that the assessment is robust and ready for regulatory submission.

4. Regulatory Reporting and Submission

• Regulatory Intelligence: Verify the submission requirements for the specific region (e.g., FDA MedWatch, EMA EudraVigilance) based on the case severity.
• Transmission: Securely transmit the ICSR via electronic submission gateways (e.g., ESG or EVWEB).
• Receipt Confirmation: Monitor and archive the acknowledgment receipts from health authorities to prove compliance.

Pro Tips & Pitfalls

• Pro Tip: Automate Workflows. Utilize AI-driven intake tools for automated data extraction from unstructured documents to reduce manual entry errors.
• Pro Tip: Audit Readiness. Always treat every case as if an auditor is reviewing it tomorrow. Maintain a "paper trail" for every clinical decision made.
• Pitfall: The "Day 0" Trap. Many firms struggle because they count Day 0 from the date the case reaches a specific department rather than the first day the company received the information. Ensure Day 0 is strictly defined at the point of initial receipt.
• Pitfall: Poor Narrative Quality. Avoid "copy-pasting" source data. A good narrative should read like a medical case study that can stand alone without the original documents.

Frequently Asked Questions (FAQ)

Q: What constitutes a "serious" adverse event? A: An event is considered serious if it results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

Q: How do we handle "blinded" clinical trial cases? A: Safety procedures dictate that the blind must be maintained for the study team, but the PV department must have a mechanism to "break the blind" if the safety of the participant depends on knowing the identity of the suspect drug.

Q: What is a signal in pharmacovigilance? A: A signal is reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Signals are identified through data mining and statistical analysis of the safety database.